GTPBP8

Across TCGA pan-cancer cohorts, GTPBP8 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated GTPBP8 data layer compared with 20 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in ovarian serous cystadenocarcinoma (OV), where higher GTPBP8 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated GTPBP8 expression acts as an unfavorable survival marker.

OV, SKCM, and SARC are the cancer types where GTPBP8 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
OV	OS	Median	II,III,IV	0.007	0.844	<.001	48	view →
SKCM	OS	Median	II,III,IV	0.202	0.735	.002	12	view →
SARC	DFS	Median	All	0.121	0.611	.041	6	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

GTPBP8–OV (OS)

Open the OV breakdown →